Document is current

Article History

Received: 1 November 2017

Accepted: 20 February 2018

First Online: 15 March 2018

Ethics approval and consent to participate

: Not applicable.

: Not applicable.

: Dr Teunissen has functioned in advisory boards of Fujirebio and Roche, received non-financial support in the form of research consumables from ADxNeurosciences and Euroimmun, performed contract research or received grants from Janssen prevention center, Boehringer, Brainsonline, AxonNeurosciences, EIP farma, Probiodrug and Roche which are all unrelated to the present work.Dr Otto gave invited talks for Teva, Virion, Fujirebio and Lilly and gave scientific advice to Axon, Biogen, Ionis, Roche and Neuroalliance.Dr Engelborghs has received unrestricted research grants from Janssen Pharmaceutica NV and ADx Neurosciences (paid to institution).Dr Herukka has no conflicts to report.Dr Lehmann received consultation honoraria from Fujirebio Europe.Dr Lewczuk received consultation and lectures honoraria from Innogenetics/Fujirebio Europe, IBL International, AJ Roboscreen, and Roche.Dr Lleó MD, PhD has received speaker honoraria from Novartis, Esteva, Nutricia and Lilly and fees for advisory board meetings for Nutricia, Novartis, Schwabe and Lilly.Dr Perret-Liaudet received funding for travel from Innogenetics/Fujirebio, Roche, Siemens and AJ Robosceen (in the context of lectures).Dr Tumani received funding for research projects, lectures and travel from Bayer, Biogen, Genzyme, Fresenius, Merck, Novartis, Roche, Siemens Health Diagnostic and Teva.Dr Wiltfang received personal fees (advisory boards or consulting) from Axon Neuroscience, Eli Lilly, Janssen-Cilag GmbH, MSD Sharp & Dohme GmbH, F. Hoffmann-La Roche.Henrik Zetterberg MD, PhD is a co-founder of Brain Biomarker Solutions in Gothenburg AB, a GU Ventures-based platform company at the University of Gothenburg. He has served on advisory boards of Roche Diagnostics, Eli Lilly and Pharmasum Therapeutics and has received a travel grant from TEVA.L. Parnetti MD, PhD has received honoraria as a member of advisory boards from Innogenetics/Fujirebio Europe, IBL International and Roche.Dr Blennow has served as a consultant or on advisory boards for Alzheon, BioArctic, Biogen, Eli Lilly, Fujirebio Europe, IBL International, Merck, Pfizer and Roche Diagnostics and is a co-founder of Brain Biomarker Solutions in Gothenburg AB, a GU Venture-based platform company at the University of Gothenburg.Dr Herukka, Dr Turner MD and Dr Verbeek have no conflicts to report.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.